Oncology Times - OncTimes Talk

Double TKI Therapy Improves Responses in MET Amplification-Driven EGFR-Mutant Non-Small Cell Lung Cancer

Contributed by Lukas

Among patients with non-small cell lung cancers driven by mutations in the epidermal growth factor receptor (EGFR), those with MET-amplification can n...

Two Drug Combination Benefits Patients with nRAS-Mutated Melanoma Refractory to Checkpoint Inhibition

Contributed by Lukas

Research presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics found that a combination of two dr...

CLIC Protein Inhibition Key to Metformin’s Anti-Neoplastic Properties

Contributed by Lukas

The Chloride Intracellular Channel 1 (CLIC1) protein appears to hold the key to understanding the anti-proliferative action of metformin, according to...

Adjuvant ATR Inhibition Prolonged Life in Patients with Relapsed Small Cell Lung Cancer

Contributed by Lukas

Dr. Takahashi talks with OncTimes Talk’s Peter Goodwin about the Phase 2 study he presented at the AACR-NCI-EORTC International Conference on Mo...

Chemotherapy Order Sets—Lessons Learned

Contributed by Lukas

Timothy Birdsall, ND, Chief Medical Information Officer at Cancer Treatment Centers of America, tells OT what goes into making the more than 300 chemo...

Mitophagy Discovered as Potential Reason for AML’s Resistance to Venetoclax

Contributed by Lukas

Acute myeloid leukemia (AML) is notoriously difficult to treat. Only 28 percent of patients survive beyond 5 years after diagnosis. Mitophagy, a proce...

Unintentional Bias of Breast Cancer Randomized Clinical Trial Interpretations Through Discontinuation Imbalance

Contributed by Lukas

Some of the big randomized clinical trials could lead to unintentional bias because of an imbalance of assigned treatment discontinuations between exp...

Trastuzumab Deruxtecan Benefits Patients with HER2-Low Metastatic Breast Cancer Irrespective of ER Expression

Contributed by Lukas

Although T-DXd had already been licensed for use in all categories of HER2 positivity, including patients with so-called HER2-low tumors (defined as h...

Artificial Intelligence Model Predicts Overall Survival in Patients with Metastatic Breast Cancer

Contributed by Lukas

A mathematical study of real-world data from 27,855 women whose breast cancer was diagnosed between 2008 and 2020 has shown that a machine-learning ar...

Axillary Dissection in Older Women With Clinically Node-Negative Breast Cancer

Contributed by Lukas

Caution was expressed at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting about potential adverse effects from one form of breast ...

Full Compliance With Adjuvant Endocrine Therapy Brings 15 Percent Superior Survival in Patients With Breast Cancer

Contributed by Lukas

Patients with breast cancer who complied fully with their adjuvant endocrine medication lived 15 percent longer than those who skipped doses, accordin...

Being Obese & Overweight Reduces Efficacy of Extended Endocrine Therapy in HR+ Breast Cancer

Contributed by Lukas

Being overweight or obese can reduce the benefit of extending adjuvant breast cancer hormone therapy in women younger than 60 years, according to rese...

ASCO 2023: Neoadjuvant Pembrolizumab Brought Big Benefit in Early-Stage Non-Small Cell Lung Cancer with Heather A. Wakelee, MD, FASCO

Contributed by Lukas

Non-small cell lung cancer was one of the big topics at the 2023 ASCO Annual Meeting where Heather Wakelee, MD, FASCO, Professor of Medicine and Chief...

ASCO 2023: How AI Can Help Physicians Communicate with Dying Patients Better & Also Reduce Costs

Contributed by Lukas

End-of-life care for patients with cancer could be significantly improved while simultaneously reducing cost according to the findings of a study from...

Targeted Adjuvant Therapy in Non-Small Cell Lung Cancer with Roy Herbst, MD PhD

Contributed by Lukas

Roy Herbst, MD PhD, Deputy Director of the Yale Cancer Center at Yale School of Medicine, talks with OncTimesTalk correspondent Peter Goodwin about hi...

Targeted Adjuvant Therapy in Non-Small Cell Lung Cancer with Roy Herbst, MD PhD

Contributed by Lukas

Roy Herbst, MD PhD, Deputy Director of the Yale Cancer Center at Yale School of Medicine, talks with OncTimesTalk correspondent Peter Goodwin about hi...

Emerging Cancer Treatments for Esophageal Cancer with Brian Henick, MD

Contributed by Lukas

Progress in esophageal cancer is forging ahead at Columbia University in New York. Brian Henick, MD, is a medical oncologist specializing in the care ...

Meet the New Oncology Times Editorial Board Chair: Stephanie L. Graff, MD, FACP

Contributed by Lukas

Today we are introducing the new Oncology Times Editorial Board Chair: Stephanie L. Graff, MD, FACP. In her new role, Graff will help Oncology Times c...

Ravi B. Parikh, MD, on How Machine Learning-Triggered Reminders Can Improve End-of-Life Care for Cancer Patients

Contributed by Lukas

When cancer advances to an incurable stage, some patients may prioritize treatment that will extend their life as long as possible, and others may pre...

Deanna Gerber, MD, on Navigating Cervical Cancer Screening

Contributed by Lukas

Despite increased screening and HPV vaccines, cervical cancer remains the fourth-leading cause of cancer death among women worldwide. Screening guidel...

January Research Review: Promising Results in HemOnc Clinical Trials

Contributed by Lukas

This episode is Research Review, a quarterly review of the research you may have missed. Today, we are covering the American Society of Hematology Ann...

ASCO 2022 Small Bytes: Dr. Alexander I. Spira on KRYSTAL-1 for Patients with Advanced/Metastatic NSCLC

Contributed by Lukas

At the ASCO 2022 Annual Meeting, Oncology Times reporter Peter Goodwin caught up with Alexander I. Spira, MD, PhD, FACP after his presentation on KRYS...

ASH 2021 Recap: COVID-19 in Patients with Acute Leukemias & Myelodysplasia In Conversation with Dr. Pinkal Desai

Contributed by Lukas

At the 2021 Annual Meeting of the American Society of Hematology, researchers presented more data on additional risks faced by patients who have acute...

Unraveling a Complex Disease: Gary K. Schwartz, MD, on Sarcoma Research Highlights, Targeted Agents & Future Directions

Contributed by Lukas

Sarcoma represents an incredibly rare group of cancers comprised of 50 histologic subtypes, with approximately 13,000 new diagnoses per year. Each his...

ASH 2022: David Sallman, MD, Discusses Positive Phase I Dose Escalation Data for PRGN-3006 UltraCAR-T in AML Patients

Contributed by Lukas

A study using chimeric antigen receptor (CAR)-T cells has proven to be safe for treating patients with relapsed or refractory acute myeloid leukemia (...

Anil K. Rustgi, MD, on the Current State of Colorectal Cancer Screening

Contributed by Lukas

Colorectal cancer is the third most diagnosed cancer and the second leading cause of cancer deaths worldwide. The current gold standard for screening,...

Small Bytes: How ctDNA Liquid Biopsies Can Detect Myeloid Malignancies & Occult Tumors

Contributed by Lukas

BARCELONA, Spain—Liquid biopsies are increasingly used to identify cancer progression and could also provide molecular evidence of higher risk for h...

Small Bytes: Phase I Study Finds Pan-AKT Inhibitor Ipatasertib Safe & Effective, Featuring Carolyn McCourt, MD

Contributed by Lukas

BARCELONA, Spain—Patients with solid tumors expressing mutated AKT oncogenes responded to therapy with a pan-AKT inhibitor—the investigational dru...

Dr. Lisa Newman on Eliminating Racial Disparities in Breast Cancer

Contributed by Lukas

In oncology today, there is an urgent need to better understand the implications of racial bias and disparities on the health outcomes of patients. Al...

HemOnc Highlights: Dr. Naveen Pemmaraju on the Benefits of Tagraxofusp for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

Contributed by Lukas

We talk to Naveen Pemmaraju, MD, about the results of the largest prospective BPDCN trial evaluating the CD123-targeted therapy tagraxofusp in adult...

5 Questions on Making Cardio-Oncology More Accessible to Diverse Patient Populations with Dr. Sandeep Mittan

Contributed by Lukas

Today on OncTimes Talk, we are getting to know a clinical researcher in 5 questions. We sat down with Sandeep Mittan, PhD, FAHA, who is a Clinical Sci...

ESMO 2022: For Desmoid Tumor, First Proven Therapy Shows Clear Benefit, “Should Become Standard”

Contributed by Lukas

PARIS, France—One of the most prominent late-breaking abstracts reported at ESMO 2022 in Paris was about a rare cancer, desmoid tumor, for which no ...

OncTimes Talk Research Review February 2022: Dr. Stephen Hahn, COVID, 2021 World Cancer Leaders’ Summit & Cervical Cancer News

Contributed by Lukas

Today we are bringing you a round up of three stories from around the world. We will start at the 2021 World Cancer Leader’s Summit, then move onto ...

ESMO 2022: PATHFINDER Presents Screening Paradigm Shift with A Blood Test to Facilitate Early Detection

Contributed by Lukas

The availability of a blood test for circulating DNA that can be used widely in healthy individuals to check for molecular signs of multiple cancers l...

OncTimes Talk Research Review August 2022: Focus on Breast Cancer

Contributed by Lukas

Journalist Peter Goodwin gives OncTimes Talk a whirlwind review of the top 2022 breast cancer research as he reports live in person from the 2022 ESMO...

Metastatic Hormone-Sensitive Prostate Cancer: Extending Life By Adding a Third Drug to Standard Regimens with Dr. Vincent Khoo

Contributed by Lukas

In this edition of OncTimes Talk we’re taking a look at: extending life in patients with metastatic hormone-sensitive prostate cancer by adding a th...

Liquid Biopsy ctDNA Prediction of Lung Cancer Relapse “Ready for Prime Time”

Contributed by Lukas

CAMBRIDGE, UK—OncTimesTalk visits genetics pioneer Nitzan Rosenfeld PhD, group leader at the Cancer Research UK Cambridge Institute, University of C...

ASCO 2022 Small Bytes Episode 3: Dr. Marla Lipsyc-Sharf on Personalized ctDNA Testing in Late, HR+, HER2-Negative Breast Cancer

Contributed by Lukas

At the ASCO 2022 Annual Meeting, Oncology Times reporter Peter Goodwin interviewed Marla Lipsyc-Sharf, MD, Medical Oncology Fellow at Dana-Farber Canc...

ASCO 2022 Small Bytes Episode 2: Dr. Julia C. Tchou on Telehealth Weight Loss Program for Breast Cancer Survivors

Contributed by Lukas

At the ASCO 2022 Annual Meeting, Oncology Times reporter Peter Goodwin caught up with Julia C. Tchou, MD, PhD, FACS, from the University of Pennsylvan...

Colleague Conversations: A Look at Germline Predisposition to Hematologic Malignancies

Contributed by Lukas

Colleague Conversations offers insights into hematology/oncology from two different perspectives: a seasoned hematologist/oncologist and a clinician e...

Refugees & Cancer Care: Ukraine, Lebanon & Beyond Featuring Dr. Richard Sullivan & Dr. Deborah Mukherji

Contributed by Lukas

As Russian forces continue to bombard Ukraine, concerns are mounting about the most vulnerable citizens there, including the ill and those with cancer...

Unpacking the Role of Emotions in Mastectomy Decisions with Clara N. Lee, MD

Contributed by Lukas

A bilateral prophylactic mastectomy for women at high risk of developing breast cancer can reduce their risk of developing the disease by up to 90 per...

Mitigating the Effects of Climate Change on Cancer Care With Robert A. Hiatt, MD, PhD

Contributed by Lukas

While the threat of climate change may conjure images of sea level rise, extreme weather patterns, and drought, the full picture of how climate change...

Roswell Park’s Candace S. Johnson & Congressman Brian Higgins on the Promise of Biden’s Cancer Moonshot

Contributed by Lukas

In early February, President Joe Biden announced that he is supercharging the Cancer Moonshot program to accelerate progress against cancer and save l...

ASH 2021 Revisited: Plenary Sessions, ZUMA-7 & COVID Vaccines

Contributed by Lukas

Today we revisit three studies presented at the ASH 2021 Annual Meeting. Primary Analysis of ZUMA-7 The 2021 American Society of Hematology Plenary Se...

ASH 2021 Recap: Multi Omics Sheds New Light on Malignant Transformation from Myeloproliferative Neoplasm to AML

Contributed by Lukas

In this episode, we bring you new research from the 2021 American Society of Hematology Annual Meeting about the cellular processes involving the muta...

Study Recap: After 6 Months, Pfizer COVID Vaccine Remains Effective Against Hospitalizations

Contributed by Lukas

A new study provides support for high effectiveness of the Pfizer COVID vaccine against hospital admissions up until around 6 months after being fully...

Colleague Conversations: Palliative Care in Oncology

Contributed by Lukas

Colleague Conversations offers insights into hematology/ oncology from two different perspectives: a seasoned hematologist/oncologist and an early-car...

Research Spotlight: MET Amplification as Driver for NSCLC

Contributed by Lukas

A new study has helped to define MET amplification as a rare but potentially actionable driver for non-small cell lung cancer (NSCLC). The paper, titl...

OncTimes Talk Research Review May 2021

Contributed by Lukas

What’s in the OncTimesTalk, May 2021 Edition? New clinical findings on: Nivolumab in gastro-esophageal cancer, CDK4/6 inhibition for breas...

How Health IT is Changing Oncology

Contributed by Lukas

Andrew Zelenetz, MD, PhD, Chief of the Lymphoma Service and Vice Chair of Medical Informatics at Memorial Sloan Kettering Cancer Center, tells OT how ...

Straight Talk with Dr. Brian J. Bolwell: Values

Contributed by Lukas

Welcome to the Oncology Times Podcast. Today on the Pod - Why do relatively few leaders live good values consistently? Why are so many people, especia...

Straight Talk with Dr. Brian J. Bolwell: Moments

Contributed by Lukas

In his recurring Oncology Times column “Straight Talk: Today's Cancer Centers,” Brian J. Bolwell, MD dispenses wisdom on how to be a better leader...

Young Investigators: Liam Holt, PhD, Examines High Compression on Cells & Cancer

Contributed by Lukas

Liam Holt, PhD, speaks in analogies when describing his work focusing on compression of cancer cells and how it affects their behavior and evolution a...

Straight Talk with Dr. Brian Bolwell: Letting it Go

Contributed by Lukas

Oncology Times sits down with Brian J. Bolwell, MD, the Chairman of the Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic Ler...

Talking About Leadership With Brian J. Bolwell, MD, FACP

Contributed by Lukas

Looking for insights on leadership? Listen to Brian J. Bolwell, MD, FACP, Chairman of the Taussig Cancer Institute and Professor of Medicine at the Cl...

A Closer Look at Ultra-Rare Cancers

Contributed by Lukas

Naveen Pemmaraju, MD, discusses the therapeutic landscape of ultra-rare cancers as well as the importance of ongoing research in these patient populat...

What I Love About Hematology/Oncology: Muzaffar H. Qazilbash, MD

Contributed by Lukas

Muzaffar H. Qazilbash, MD, from The University of Texas MD Anderson Cancer Center, Houston, discusses what he loves about hematology/oncology, includi...

What I Love About Hematology/Oncology: Margaret Kasner, MD, MSCE

Contributed by Lukas

HemOnc Times Editorial Advisory Board Member Margaret ‘Margie’ Kasner, MD, MSCE, of Sidney Kimmel Cancer Center – Jefferson Health, Philadelphia...

The Role of Patient Education in Survivorship Care

Contributed by Lukas

Patricia A. Ganz, MD, explains why implementing standards for survivorship care is just as important as other patient education efforts on the cancer ...

How CancerLinQ Will Change Patient Care

Contributed by Lukas

George W. Sledge, Jr., MD—a CancerLinQ Advisory Group member—explains how the rapid learning system will affect day-to-day oncology. Listen to wh...

How Drug Shortages Affect Oncology

Contributed by Lukas

Richard L. Schilsky, MD—who’s led ASCO’s charge in urging Congress to take notice of the increasing scarcities of needed cancer drugs—discusse...

The Thinking Behind ASCO’s Top Five List

Contributed by Lukas

Lowell E. Schnipper, MD, Chair of ASCO’s Cost of Care Taskforce and Chief of Hematology/Oncology at Beth Israel Deaconess Medical Center in Boston, ...

The Value of In-Person Meetings

Contributed by Lukas

Clifford A. Hudis, MD, Chief of the Breast Cancer Medicine Service of Memorial Sloan-Kettering Cancer Center and ASCO’s 2012-2013 President-Elect, e...

Oncology Practices Expect Big Change

Contributed by Lukas

Thomas L. Whittaker, MD, Immediate Past President of the Association of Community Cancer Centers, explains the implications of survey results that sho...

Cancer’s Existential Impact on Survivors

Contributed by Lukas

William Breitbart, MD, Acting Chair of the Department of Psychiatry and Behavioral Sciences at Memorial Sloan-Kettering Cancer Center, explains how a ...

How Should Physicians Be Paid?

Contributed by Lukas

Steven Schroeder, MD, Chairman of the newly formed National Commission on Physician Payment Reform, discusses the commission’s upcoming report on ho...

Integrating Palliative & Standard Care

Contributed by Lukas

Thomas J. Smith, MD, Professor of Oncology and Director of Palliative Care at Johns Hopkins Medical Institutions, explains the benefits of making pall...

Metastatic Colorectal Cancer: Capecitabine Equivalent to 5-FU in Irinotecan/Bevacizumab Combos

Contributed by Lukas

Michel Ducreux, Head of the GI Service at Institut Gustave Roussy, talks about the new evidence and its clinical implications, as reported in his Phas...

The Importance of “Competitive Mortality” in Oncology Care

Contributed by Lukas

Steven Tucker, MD, a prostate cancer specialist, discusses “competitive mortality”—how understanding the other conditions in addition to cancer,...

Final Rule for Medicare ACOs

Contributed by Lukas

Matt Brow, U.S. Oncology’s top public policy official, breaks down the details of the Medicare Shared Savings Program—the federal government’s f...

Will CMS Cast Its Eye Toward Oncology?

Contributed by Lukas

Reginald Williams II, an Avalere Health Director, discusses his organization’s analysis of how the oncology landscape may be the next topic of scrut...

Multiple Myeloma: Big Survival Gains from Novel Agents 'in the Real World'

Contributed by Lukas

Evangelos Terpos, speaking at the European Hematology Association 2010 Congress in Barcelona, discusses his group's encouraging findings based on 10 y...

From the European Hematology Association 2010 Congress: For Patients with Follicular Lymphoma, Rituximab Maintenance Therapy Cuts Risk of Recurrence in Half (Phase III PRIMA Study)

Contributed by Lukas

Speaking at the meeting in Barcelona, Gilles Salles of the University of Lyon discusses the results showing that patients who had achieved remissions ...

OT Clinical Advisory Editor for Hematology/Oncology Mikkael Sekeres, MD, MS

Contributed by Lukas

Dr. Sekeres, Director of the Leukemia Program at the Cleveland Clinic Taussig Cancer Institute and Chair of the Hematology/Oncology Pharmacy & Therape...

OT Clinical Advisory Editor for Oncology Ramaswamy Govindan, MD

Contributed by Lukas

Dr. Govindan, Professor of Medicine and Director of the Thoracic Medical Oncology Program at Washington University Alvin J. Siteman Cancer Center, ela...

Treatment Recommendations for High- & Low-Risk Early Breast Cancer: New Data from EBCC 7, the European Breast Cancer Conference

Contributed by Lukas

Lori Pierce on breast-conserving therapy + adjuvant chemotherapy for BRCA 1 & 2 carriers; Annette Heemskerk-Gerritsen on the relationship between cont...

Pregnancy & Breast Cancer: New Updates from EBCC 7, the European Breast Cancer Conference

Contributed by Lukas

Hatem Azim on how pregnancy after breast cancer is safe and possibly protective; Angela Ives on why recent -- but not current -- pregnancy worsens br...

Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue!

Contributed by Lukas

Cornelis van de Velde at ECCO15-ESMO34 on the largest comparison of an aromatase inhibitor with tamoxifen as initial adjuvant therapy for patients wit...

Longer Follow-up Reveals: Aspirin Prevents Cancer in Lynch Syndrome

Contributed by Lukas

John Burn talking at ECCO15-ESMO34 in Berlin about his international study showing that aspirin prevented the development of Hereditary Non-Polyposis ...

Research Policy Expert: Overhaul Cancer Research Priorities Globally Now!

Contributed by Lukas

Richard Sullivan at ECCO15-ESMO34 on the need for research that is more “trans-national” and funded globally to shift priorities to prevention, su...

Swedish Registry Study Shows Hormone Therapy for Prostate Cancer Increased All Cardiovascular Mortality

Contributed by Lukas

Mieke Van Hemelrijck at ECCO15-ESMO34 on findings that cardiovascular mortality from heart failure and arrhythmia in addition to ischemic heart diseas...

The Disappointment of the NSABP C-08 Trial

Contributed by Lukas

Norman Wolmark on the study's frustrating but unequivocal results showing that bevacizumab did not extend disease-free survival in adjuvant therapy fo...

Advanced Biliary Cancer Controlled with Cetuximab Added to GEMOX

Contributed by Lukas

Éveline Boucher of Centre Eugene Marquis in France on the encouraging preliminary results of her Phase II open-label study of 101 patients reported a...

Stage IV Pancreatic Islet Cell Tumors: Sunitinib Doubles Progression-Free Survival in Phase III Study

Contributed by Lukas

Eric Raymond of Beaujon University Hospital in France discusses his study reported at the ESMO World Congress on Gastrointestinal Cancer

KRAS-Driven Selection of Molecular Therapy for Metastatic Colorectal Cancer: Choosing Between Bevacizumab, Cetuximab, Panitumomab, or a Combination

Contributed by Lukas

Interviewed at the Palm Beach Cancer Symposium, John Macdonald, Chief Medical Officer of Aptium Oncology in Los Angeles, talks about his latest data o...

CML: Hagop Kantarjian on Treating Patients with the T315I Mutation

Contributed by Lukas

Also: (1) Feasibility of patients becoming pregnant while having TKI treatment after having stable disease for at least two years; and (2) Decreased n...

Oropharyngeal Cancer: Better Outlook with HPV-Directed Therapies

Contributed by Lukas

Marshall Posner, MD, talking from Palm Beach Cancer Symposium: Increased prevalence of HPV-related oropharyngeal cancers, more responsive to treatment...

Breast Cancer: St. Gallen Meeting Endorses Multi-Gene Assays for Refining Chemo Decision

Contributed by Lukas

Also from the Palm Beach Cancer Symposium, Kathy Albain, MD, talks about the St. Gallen consensus meeting’s updated recommendations about adjuvant t...

The Smartest Oncologist in the World? – Well, at least in the US!

Contributed by Lukas

Stanley H. Winokur, MD, on his clever, fun, and ever-evolving one-minute daily Internet quiz that lets oncologists test their knowledge & compete agai...

Cancer-Related Fatigue

Contributed by Lukas

Paddy Stone of St. George's Hospital, University of London, & David Cella from Northwestern University Feinberg School of Medicine about the effective...

Bilateral Prophylactic Mastectomy for DCIS

Contributed by Lukas

Todd Tuttle from University of Minnesota & Abram Recht from Beth Israel Deaconess Medical Center on the surprisingly big recent increase in the use of...

10th European Congress on Perspectives in Lung Cancer, Brussels

Contributed by Lukas

Silvia Novello and Giorgio Scagliotti on harnessing insulin-like growth factor receptor inhibition in a Phase II study that showed clinical activity o...

More from the ASH Annual Meeting!

Contributed by Lukas

Greater Role for Umbilical Cord Blood in Adult Transplants (Mary Eapen, commentary from Armand Keating). Ex Vivo Expansion of Cord Blood Derived Pro...

Program 4, Day 4, Monday Dec 8

Contributed by Lukas

Prof Giuseppe Saglio of the University of Turin and San Luigi Gonzaga Hospital in Italy on nilotinib as a new standard of care for chronic myeloid leu...

Program 3, Monday Dec 7

Contributed by Lukas

George Canellos on aggressive chemotherapy's failure to benefit patients with high-risk B-cell lymphoma. Massimo Martelli of University of Perugia on ...

Program 2, Sunday Dec. 6

Contributed by Lukas

George Canellos, What’s hot from the ASH Plenary Session. Maria-Victoria Mateos of Salamanca University in Spain on melphalan as the better partner ...

Program 1, First Day, Dec. 5

Contributed by Lukas

George Canellos: Raising the curtain on ASH 2009. Jorge Cortes, M. D. Anderson Cancer Center, on omacetaxine for CML patients with resistance to imati...

ASH Annual Meeting

Contributed by Lukas

Peter Goodwin talks to key investigators Francesco Zaja (on rituximab for ITP); Hannes Wandt (on how platelet transfusions may be able to be withheld ...

NCRI Conference, ASCO Annual Meeting, and Perspectives in Lung Cancer European Congress

Contributed by Lukas

New research for advanced NSCLC showing that combining monoclonal antibodies and chemotherapy can extend life: OTBN Editor Peter Goodwin and Producer ...